EBOS GROUP LIMITED — Earnings Release 2023

Feb 21, 2023

Results announcement

==> picture [101 x 49] intentionally omitted <==

==> picture [120 x 76] intentionally omitted <==

(for Equity Security issuer/Equity and Debt Security issuer)

Results for announcement to the market
Name of issuer	EBOS Group Limited
Reporting Period	6 months to 31 December 2022
Previous Reporting Period	6 months to 31 December 2021
Currency	AUD
	Amount (AUD $000s)	Percentage change
Revenue from continuing operations	$6,145,722	17.0%
Total Revenue	$6,145,722	17.0%
Underlying net profit from continuing operations attributable to security holders1	$141,626	29.6%
Net profit/(loss) from continuing operations	$132,198	29.8%
Total net profit/(loss)	$132,198	29.8%
Final Dividend
Amount per Quoted Equity Security	NZD $0.53000000
Imputed amount per Quoted Equity Security	NZD $0.05152778
Record Date	03 March 2023
Dividend Payment Date	17 March 2023
	Current period	Prior comparable period
Net tangible assets per Quoted Equity Security2	AUD($3.79)	AUD$2.18
A brief explanation of any of the figures above necessary to enable the figures to be understood	Refer to the Interim Report, Results Presentation, Media Release and Letter to Shareholders for EBOS Group Limited for the six month period to 31 December 2022, issued on 22 February 2023.
Authority for this announcement
Name of person authorised to make this announcement	Janelle Cain
Contact person for this announcement	Janelle Cain
Contact phone number	+61 3 9918 5370
Contact email address	Janelle.Cain@ebosgroup.com
Date of release through MAP	22 February 2023

Unaudited condensed consolidated interim financial statements accompany this announcement.

1 Underlying earnings for the 31 December 2022 period excludes the amortisation (non-cash) expense attributable to the LifeHealthcare acquisition purchase price accounting (PPA) of finite life intangible assets ($13.5m pre tax, $9.4m post tax). Underlying earnings for the 31 December 2021 period excludes transactions costs incurred on M&A ($7.8m pre tax, $7.4m post tax). Refer to Appendix 1 for reconciliation between reported and underlying earnings.

2 Net Tangible Assets excludes A$291.4m (December 2021: A$237.4m) of Right of Use assets, although includes A$312.1m (December 2021: A$256.7m) of lease liabilities in relation to the adoption of NZ IFRS 16 ‘Leases’ .

Appendix 1:

==> picture [429 x 330] intentionally omitted <==

----- Start of picture text -----

Reconciliation of Reported vs Underlying Earnings 31 Dec 2022 31 Dec 2021 Change
(Unaudited) AUD $000 AUD $000 %
Reported EBITDA 289,180 199,881 44.7%
Add back one-off items incurred during the period1 - 7,771
Underlying EBITDA 289,180 207,652 39.3%
Reported EBIT 226,018 161,313 40.1%
1 -
Add back amortisation (non-cash) on LifeHealthcare PPA 13,469
Add back one-off items incurred during the period1 - 7,771
Underlying EBIT 239,487 169,084 41.6%
Reported PBT 192,627 147,513 30.6%
1 -
Add back amortisation (non-cash) on LifeHealthcare PPA 13,469
Add back one-off items incurred during the period1 - 7,771
Underlying PBT 206,096 155,284 32.7%
Reported Net Profit after Tax (NPAT) attributable to owners
132,198 101,866 29.8%
of the Company
Add back amortisation (non-cash) on LifeHealthcare PPA1 -
9,428
(net of tax and after non-controlling interests)
Add back one-off items incurred during the period1 (net of tax -
7,405
and after non-controlling interests)
Underlying Net Profit after Tax (NPAT) attributable to
141,626 109,271 29.6%
owners of the Company
----- End of picture text -----

1 Underlying EBITDA, Underling EBIT, Underlying PBT and Underlying Net Profit after Tax attributable to the owners of the Company are non-GAAP measures. Underlying earnings for the 31 December 2022 period excludes the amortisation (non-cash) expense attributable to the LifeHealthcare acquisition purchase price accounting (PPA) of finite life intangible assets ($13.5m pre tax, $9.4m post tax). Underlying earnings for the 31 December 2021 period excludes transactions costs incurred on M&A ($7.8m post tax, $7.4m post tax).